Theranostic systems that permit both diagnosis and treatment in vivo are highly appealing means by which to meet the demands of precision medicine. However, most such systems remain subject to issues related to complex molecular design and synthesis, potential toxicity, and possible photoactivity changes. Herein, a novel supramolecular theranostic strategy involving biomarker protein activation (BPA) and a host–guest strategy is proposed. To exemplify BPA, a facile “one-for-all” nanotheranostic agent for both albumin detection and cancer treatment is demonstrated, which utilizes a nanoparticulate heavy-atom-free BODIPY dye derivative (B4 NPs). The fluorescence and photoactivity of BODIPY dyes are completely suppressed by aggregation-induced self-quenching in the nanoparticulate state. However, a Balb/c nude mouse model is used to confirm that following the disassembly of injected B4 NPs, BODIPY specifically binds albumin in vivo, accompanied by significantly enhanced biocompatibility and photothermal conversion efficiency. More importantly, this supramolecular host–guest BPA strategy enables the resultant nanoplatform to act as a facile and efficient strategy for photodynamic and photothermal immunotherapy.
Bibliographical noteFunding Information:
H.-B.C., H.D., and X.T. contributed equally to this work. The authors acknowledge the National Natural Science Foundation of China (21502195, 51972003, 21671178, U1704256), the financial supports from Fundamental Research Funds for the Central Universities (11170042105, buctrc202004), Intergovernmental International Cooperation Project of the Ministry of Science and Technology (2018YFE0192500), and Zhongyuan Science and Technology Innovation Leading Talents (214200510017). J.Y. was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2021R1A6A1A10039823). All experimental animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Peking University and approved by the Animal Ethics Committee of Biomedical Ethics Committee of Peking University (the approval number is LA2019078). Note: Hong-Bo Cheng, Jing Zhao, Liming Zhou, and Yuguang Wang were marked as corresponding authors on March 17, 2022, after initial publication online.
© 2022 Wiley-VCH GmbH
- cancer therapy
- enhanced photothermal efficiency
- heavy-atom-free BODIPY
- host–guest strategy